Skip to main content
SpringerLink
Log in

Peritoneal Carcinomatosis from Ovarian Cancer

  • Chapter
Treatment of Peritoneal Surface Malignancies

Part of the book series: Updates in Surgery ((UPDATESSURG))

  • 901 Accesses

Abstract

Peritoneal carcinomatosis (PC) is the most impressive and frequent form of locoregional spread of epithelial ovarian cancer (EOC). For much of its natural history, the disease remains confined to the peritoneal district, thus representing the target for various combinations of surgery and systemic or locoregional chemotherapy (CHT). PC is evident both in the primary setting, i.e., in patients first treated for locally advanced EOC, or as a recurrence in patients previously treated for OC at any Fédération Internationale de Gynécologie et Obstétrique (International Federation of Gynecology and Obstetrics) (FIGO) stage.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104

    CAS  PubMed  Google Scholar 

  2. Shih KK, Chi DS (2010) Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol 21:75–80

    Article  PubMed Central  PubMed  Google Scholar 

  3. Sugarbaker PH (1996) Complete Parietal and Visceral Peritonectomy of the Pelvis for advanced primary and recurrent ovarian cancer. Cancer Treat Res 81-75-87

    Google Scholar 

  4. Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosisi. Cancer Treat Res 82:359–374

    Article  CAS  PubMed  Google Scholar 

  5. Hoskins WJ, McGuire WP, Brady MF et al (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170:974–979

    Article  CAS  PubMed  Google Scholar 

  6. Chi DS, Eisenhauer EL, Lang J et al (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecologic Oncology 103:559–564

    Article  CAS  PubMed  Google Scholar 

  7. Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259

    Article  PubMed  Google Scholar 

  8. Eisenkop SM, Friedman RL, Wang HJ (1995) Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 76:1606–1614

    Article  CAS  PubMed  Google Scholar 

  9. Cormio G, di Vagno G, Cazzolla A et al (1999) Surgical treatment of recurrent ovarian cancer:report of 21 cases and a review of the literature. Eur J Obstet Gynecol Reprod Biol 86:185–188

    Article  CAS  PubMed  Google Scholar 

  10. Eisenkop SM, Friedman RL, Spirtos NM (2000) The role of secondary cytoreductive surgery in the treatment of patients with re- current epithelial ovarian carcinoma. Cancer 88:144–153

    Article  CAS  PubMed  Google Scholar 

  11. Gadducci A, Iacconi P, Cosio S, Fanucchi A et al (2000) Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovar- ian cancer. Gynecol Oncol 79:344–349

    Article  CAS  PubMed  Google Scholar 

  12. Gronlund B, Lundvall L, Christensen IJ et al (2005) Surgical cytoreduction in recurrent ovarian carcinoma in pa- tients with complete response to paclitaxel-platinum. Eur J Surg Oncol 31:67–73

    Article  CAS  PubMed  Google Scholar 

  13. Onda T, Yoshikawa H, Yasugi T et al (2005) Secondary cytoreductive surgery for recurrent epi- thelial ovarian carcinoma: proposal for patients selection. Br J Cancer 92:1026–1032

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Benedetti Panici P, De Vivo A, Bellati F et al (2007) Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 14:1136–1142

    Article  PubMed  Google Scholar 

  15. Oksefjell H, Sandstad B, Trope C (2009) The role of secondary cytor- eduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 20:286–293

    Article  CAS  PubMed  Google Scholar 

  16. Tian WJ, Jiang R, Cheng X et al (2010) Surgery in re- current epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1–1 cm after secondary cytoreduction. J Surg Oncol 101:244–250

    PubMed  Google Scholar 

  17. Tay EH, Grant PT, Gebski V, Hacker NF (2002) Secondary cytor- eductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 99:1008–1013

    Article  PubMed  Google Scholar 

  18. Bristow RE, Puri I, Chi DS (2009) Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 112:265–274

    Article  PubMed  Google Scholar 

  19. Leitao MM Jr, Kardos S, Barakat RR, Chi DS (2004) Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol 95:181–188

    Article  PubMed  Google Scholar 

  20. Shih KK, Chi DS, Barakat RR, Leitao MM Jr (2010) Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol 117:330–335

    Article  CAS  PubMed  Google Scholar 

  21. Karam AK, Santillan A, Bristow RE et al (2007) Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol Oncol 104:377–380

    Article  PubMed  Google Scholar 

  22. Fotopoulou C, Savvatis K, Kosian P et al (2003) Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter? Br J Cancer 108:32–38

    Article  Google Scholar 

  23. Chi DS, Eisenhauer EL, Zivanovic O et al (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114:26–31

    Article  PubMed  Google Scholar 

  24. Di Giorgio A, Cardi M, Biacchi D et al (2013) Depth of colorectal-wall invasion and lymphnode involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases. World J Surg Oncol 11:64

    Article  PubMed Central  PubMed  Google Scholar 

  25. Park JY, Seo SS, Kang S, Lee KB et al (2006) The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol 103:977–984

    Article  PubMed  Google Scholar 

  26. Scarabelli C, Gallo A, Franceschi S (2000) Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 88:389–397

    Article  CAS  PubMed  Google Scholar 

  27. Fagotti A, Ferrandina G, Fanfani F et al (2006) A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 13:1156–1161

    Article  PubMed  Google Scholar 

  28. Bakrin N, Cotte E, Golfier F et al (2012) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol 19:4052–4058

    Article  CAS  PubMed  Google Scholar 

  29. Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, Abboud K, Meeus P, Ferron G, Quenet F, Marchal F, Gouy S, Morice P, Pomel C, Pocard M, Guyon F, Porcheron J, Glehen O; FROGHI (FRench Oncologic and Gynecologic HIPEC) Group (2013) Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicenter retrospective cohort study of 566 patients. Eur J Surg Oncol 39:1435–1443

    Article  CAS  PubMed  Google Scholar 

  30. Eisenkop SM, Spirtos NM, Lin WC (2006) “Optimal” cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 103:329–335

    Article  PubMed  Google Scholar 

  31. Bijelic L, Yan TD, Sugarbaker PH (2008) Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J Surg Oncol 98:295–299

    Article  PubMed  Google Scholar 

  32. Chua TC, Robertson G, Liauw W et (2009) Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol 135:1637–1645

    Article  PubMed  Google Scholar 

  33. de Bree E, Helm CW (2012) Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data. Expert Rev Anticancer Ther 12:895–911

    Article  PubMed  Google Scholar 

  34. Helm CW, Richard SD, Pan J, Bartlett D et al (2010) Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer 20:61–69

    Article  PubMed  Google Scholar 

  35. Deraco M, Kusamura S, Virzi S et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol 122:215–220

    Article  PubMed  Google Scholar 

  36. Barlin JN, Dao F, Bou Zgheib N et al (2012) Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cis-platin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 125:621–624

    Article  CAS  PubMed  Google Scholar 

  37. Onda, T, Yoshikawa, H (2011) Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions. Expert Review of Anticancer Therapy 11:1053–1067

    Article  PubMed  Google Scholar 

  38. Goff BA (2013) Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol 24:83–91

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Chan JK, Urban R, Hu JM et al (2007) The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer 96:1817–1822

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J. Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom; Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (2010) Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 28:1733–1739

    Article  PubMed  Google Scholar 

  41. Pereira A, Perez-Medina T, Magrina JF et al (2012) The role of lymphadenectomy in nodepositive epithelial ovarian cancer. Int J Gynecol Cancer 22:987–992

    Article  PubMed  Google Scholar 

  42. Sakai K, Kajiyama H, Umezu T (2012) Is there any association between retroperitoneal lymphadenectomy and survival benefit in advanced stage epithelial ovarian carcinoma patients? J Obstet Gynaecol Res 38:1018–1023

    Article  PubMed  Google Scholar 

  43. Bae JH, Lee JM, Ryu KS et al (2007) Treatment of ovarian cancer with paclitaxel- or carbo-platin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 106:193–200

    Article  CAS  PubMed  Google Scholar 

  44. Gori J, Castano R, Toziano M et al (2005) Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 15:233–239

    Article  CAS  PubMed  Google Scholar 

  45. Kim JH, Lee JM, Ryu KS et al (2010) Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol 101:149–155

    CAS  PubMed  Google Scholar 

  46. Pomel C, Ferron G, Lorimier G et al (2010) Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol 36:589–593

    Article  CAS  PubMed  Google Scholar 

  47. Frenel JS, Leux C, Pouplin L et al (2011) Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. J Surg Oncol 103:10–16

    Article  PubMed  Google Scholar 

  48. Di Giorgio A, Naticchioni E, Biacchi D et al (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113:315–325

    Article  PubMed  Google Scholar 

  49. Ryu KS, Kim JH, Ko HS et al (2004) Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 94:325–332

    Article  CAS  PubMed  Google Scholar 

  50. Rubin SC, Randall TC, Armstrong KA et al (1999) Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 93:21–24

    Article  CAS  PubMed  Google Scholar 

  51. Harter P, Hahmann M, Lueck HJ et al (2009) Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOPI Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 16:1324–1330

    Article  CAS  PubMed  Google Scholar 

  52. Cascales Campos P, Gil J, Parrilla P (2013) Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer. Eur J Surg Oncol p ii: S0748-7983(13)00752-X

    Google Scholar 

  53. Glehen O, Osinsky D, Cotte E et al (2003) Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 10:863–869

    Article  CAS  PubMed  Google Scholar 

  54. Hansson J, Graf W, Pahlman L et al (2009) Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 35:202–208

    Article  CAS  PubMed  Google Scholar 

  55. Chan DL, Morris DL, Rao A, Chua TC (2012). Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Management and Research 4:413–422

    PubMed Central  PubMed  Google Scholar 

  56. Munoz-Casares FC, Rufian S, Rubio MJ et al (2009) The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol 11:753–759

    Article  PubMed  Google Scholar 

  57. Fagotti A, Costantini B, Petrillo M et al (2012) Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecologic Oncology 127:502–505

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

    Angelo Di Giorgio

Authors
  1. Angelo Di Giorgio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Sammartino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierandrea De Iaco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelo Di Giorgio .

Editor information

Editors and Affiliations

  1. Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

    Angelo Di Giorgio

  2. Department of Medical, Surgical, and Neurological Sciences, University of Siena, Siena, Italy

    Enrico Pinto

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Italia

About this chapter

Cite this chapter

Di Giorgio, A., Sammartino, P., De Iaco, P. (2015). Peritoneal Carcinomatosis from Ovarian Cancer. In: Di Giorgio, A., Pinto, E. (eds) Treatment of Peritoneal Surface Malignancies. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-5711-1_20

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5711-1_20

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5710-4

  • Online ISBN: 978-88-470-5711-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation